Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Pfizer has struck a $2 billion deal with YaoPharma to develop and commercialize a phase 1 small-molecule GLP-1 receptor agonist for chronic weight management [1]
doi: 10.1186/1471-2164-13-274 115
Some products are reviewed through a single signaling pathway
Efficacy of levo carnitine and alpha lipoic acid in ameliorating the decline in mitochondrial enzymes during aging
When AOD 9604 binds to beta-3 adrenergic receptors on white fat cells, it triggers a cascade that starts with adenylyl cyclase activation
In laboratory models, it is frequently investigated alongside other metabolic analytes to see how they work together to synchronize neuroendocrine signals
US$ 1394.50
Sold : Login>>
